By accessing and printing a voucher or coupon for a product from this application for an eligible patient, you acknowledge that you are authorized to prescribe the product for its intended use. Please note that Akorn does not recommend the use of any product in a manner inconsistent with the Prescribing Information.


Due to requirements that Vermont imposes on pharmaceutical manufacturers’ interactions with health care professionals, health care professionals that are authorized to prescribe and licensed to provide health care in Vermont should not access or print vouchers or coupons from this application. Vermont health care professionals may contact the Akorn Customer Service Center at 1-800-932-5676 to request available vouchers or coupons for their appropriate patients.

I acknowledge the above notices. I am not a Vermont health care professional.



AzaSite helps simplify dosing with the fewest drops approved to treat bacterial conjunctivitis3–5

  • AzaSite has a simple dosing schedule—9 drops. 7 days.

AzaSite is dosed as a viscous drop in the affected eye

  • AzaSite is a 1% sterile aqueous topical ophthalmic solution of azithromycin formulated in DuraSite® (polycarbophil, edetate disodium, sodium chloride)
3. Besivance [prescribing information]. Tampa, FL: Bausch & Lomb Inc; 2012.
4. Moxeza [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc; 2012.
5. Vigamox [prescribing information]. Fort Worth, TX: Alcon Laboratories, Inc; 2011.

Important Safety Information

AzaSite® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms:

CDC coryneform group G*
Haemophilus influenzae
Staphylococcus aureus
Streptococcus mitis group
Streptococcus pneumoniae
* Efficacy for this organism was studied in fewer than 10 infections.


Hypersensitivity to any component of this product.


Topical Ophthalmic Use Only. NOT FOR INJECTION. AzaSite is indicated for topical ophthalmic use only, and should not be administered systemically, injected subconjunctivally, or introduced directly into the anterior chamber of the eye.

Anaphylaxis and Hypersensitivity with Systemic Use of Azithromycin In patients receiving systemically administered azithromycin, serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Stevens- Johnson syndrome and toxic epidermal necrolysis have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported. The potential for anaphylaxis or other hypersensitivity reactions should be considered based on known hypersensitivity to azithromycin when administered systemically.

Growth of Resistant Organisms with Prolonged Use

As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and where appropriate, fluorescein staining.

Avoidance of Contact Lenses

Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.


Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice. The data described below reflect exposure to AzaSite in 698 patients. The population was between 1 and 87 years old with clinical signs and symptoms of bacterial conjunctivitis. The most frequently reported ocular adverse reaction reported in patients receiving AzaSite was eye irritation. This reaction occurred in approximately 1-2% of patients. Other adverse reactions associated with the use of AzaSite were reported in less than 1% of patients and included ocular reactions (blurred vision, burning, stinging and irritation upon instillation, contact dermatitis, corneal erosion, dry eye, eye pain, itching, ocular discharge, punctate keratitis, visual acuity reduction) and non-ocular reactions (dysgeusia, facial swelling, hives, nasal congestion, periocular swelling, rash, sinusitis, urticaria).



Pregnancy Category B. Reproduction studies have been performed in rats and mice at doses up to 200 mg/kg/day. The highest dose was associated with moderate maternal toxicity.

These doses are estimated to be approximately 5,000 times the maximum human ocular daily dose of 2 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.

Pediatric Use

The safety and effectiveness of AzaSite solution in pediatric patients below 1 year of age have not been established. The efficacy of AzaSite in treating bacterial conjunctivitis in pediatric patients one year or older has been demonstrated in controlled clinical trials [see Clinical Studies (14)].

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.


Store unopened bottle under refrigeration at 2° to 8 °C (36° to 46°F).Once the bottle is opened, store at 2° to 25° C (36 ° to 77°F) for up to 14 days. Discard after the 14 days.

Before prescribing AzaSite® (azithromycin ophthalmic solution), please read the Prescribing Information. The Patient Information also is available.

The information on this site is intended for health care professionals in the United States and is not intended for the general public.